ArticleCureus2025
Ductal Adenocarcinoma of the Prostate Presenting With Bladder Invasion and Bone Metastasis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal adenocarcinoma of the prostate (PDA) is a rare and aggressive variant of prostate cancer with a tendency for advanced local invasion and atypical metastatic spread. We report a case of a 54-year-old male presenting with urinary symptoms and significant weight loss. Imaging revealed a pelvic mass involving the prostate and bladder, with bone metastases to the pelvis and femur. Histopathological examination of transurethral resection specimens demonstrated ductal architecture. Immunohistochemistry showed α-Methylacyl-CoA racemase (AMACR) positivity, patchy cytokeratin 7 (CK7) expression, and negative prostate-specific antigen (PSA) and GATA-binding protein 3 (GATA3). Despite the unusual immunohistochemistry profile, the findings supported a diagnosis of PDA. The patient received radiotherapy and hormonal treatment, resulting in a marked PSA decline (PSA levels declined from 19.94 ng/mL to 0.34 ng/mL over eight months, representing a reduction of approximately 98.3%). This case highlights the diagnostic complexity of PDA, particularly when immunohistochemical findings deviate from classical patterns, and underscores the need for an integrated diagnostic approach in managing aggressive prostate cancer variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.